Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis. Munoz-Vendrell A, Arroyo-Pereiro P, Leon I, Bau L, et al. J Neurol 2026;273:412.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Munoz-Vendrell A, Arroyo-Pereiro P, Leon I, Bau L, et al. Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis. J Neurol 2026;273:412.
PMID: 42332277